PARAMUS, NJ: April 14, 2023,–NS Pharma, Inc. announced today the U.S. Food & Drug Administration (FDA)has agreed to the planned Phase II study of NS-089/NCNP-02 for Duchenne muscular dystrophy. NS-089/NCNP-02 […]
CureDuchenne and PicnicHealth Announce Real-World Evidence-Focused Partnership to Incorporate Participant Medical Records into CureDuchenne Link
As you may have read in the news, Sarepta Therapeutics today announced an update from the FDA on the review of SRP-9001, Sarepta’s experimental gene therapy for Duchenne muscular dystrophy. They shared the following information:
Join Edgewise’s Chief Scientific Officer and Chief Medical Officer to discuss the clinical development program for EDG-5506, a myosin modulator, that aims to prevent muscle damage in Becker and Duchenne […]
Dyne Therapeutics, who received early funding from CureDuchenne, has received FDA Orphan Drug and Rare Pediatric Designations for DYNE-251 for the Treatment of Duchenne Muscular Dystrophy.
CureDuchenne’s Second Annual “Napa in Miami” Wine Tasting and Auction Raises More Than $1.2 Million to Help Find a Cure for Duchenne Muscular Dystrophy
VILTEPSO: AN FDA-APPROVED TREATMENT FOR PATIENTS WITH DUCHENNE MUSCULAR DYSTROPHY (DMD) AMENABLE TO EXON 53 SKIPPING This is a pre-recorded webinar with CureDuchenne, NS Pharma and guest speaker Dr. Mathula […]
First CureDuchenne Clinic Opens in Greater Dallas to Provide Specialized Care for Underserved Duchenne Muscular Dystrophy Patients
CureDuchenne Ventures Invests in hC Bioscience and its Novel tRNA-Based Therapeutic Approach for Duchenne Muscular Dystrophy
